Artiva Biotherapeutics (ARTV) Company Overview

Profile

Full Name:

Artiva Biotherapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Indexes:

Not included

Description:

Artiva Biotherapeutics is a biotechnology company focused on developing innovative cell therapies for cancer treatment.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 30, 24 HC Wainwright & Co.
Buy
Nov 13, 24 Needham
Buy
Aug 30, 24 Needham
Buy
Aug 13, 24 Wedbush
Outperform
Aug 13, 24 TD Cowen
Buy
Aug 13, 24 Needham
Buy
Aug 13, 24 Jefferies
Buy
Aug 13, 24 Cantor Fitzgerald
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
ARTV
globenewswire.comNovember 12, 2024

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
ARTV
globenewswire.comNovember 11, 2024

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 3:30 p.m. GMT, in London, UK.

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
ARTV
globenewswire.comOctober 22, 2024

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors.

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
ARTV
globenewswire.comAugust 29, 2024

Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indications Treated first patient in Artiva sponsored Phase 1/1b trial in patients with class III or IV lupus nephritis (LN) and expanded trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent progress. “Artiva is at an inflection point as we advance AlloNK® in clinical development across multiple autoimmune indications and transition to a publicly traded company,” said Fred Aslan, M.D.

This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
ARTV
fool.comAugust 29, 2024

Artiva has two-bagger potential in the eyes of multiple Wall Street analysts. Its cell therapies could provide a much more efficient treatment of autoimmune diseases.

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
ARTV
benzinga.comAugust 13, 2024

In July, Artiva Biotherapeutics, Inc. ARTV priced its upsized initial public offering of 13.92 million shares at $12.00 per share, with gross proceeds of approximately $167.0 million.

Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares
Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares
Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares
ARTV
247wallst.comJuly 28, 2024

24/7 Wall St. Insights In the past week or so, initial public offerings at a biotech and an investment management firm attracted huge insider buying.

FAQ

  • What is the ticker symbol for Artiva Biotherapeutics?
  • Does Artiva Biotherapeutics pay dividends?
  • What sector is Artiva Biotherapeutics in?
  • What industry is Artiva Biotherapeutics in?
  • What country is Artiva Biotherapeutics based in?
  • Is Artiva Biotherapeutics in the S&P 500?
  • Is Artiva Biotherapeutics in the NASDAQ 100?
  • Is Artiva Biotherapeutics in the Dow Jones?
  • When was Artiva Biotherapeutics's last earnings report?
  • When does Artiva Biotherapeutics report earnings?
  • Should I buy Artiva Biotherapeutics stock now?

What is the ticker symbol for Artiva Biotherapeutics?

The ticker symbol for Artiva Biotherapeutics is NASDAQ:ARTV

Does Artiva Biotherapeutics pay dividends?

No, Artiva Biotherapeutics does not pay dividends

What sector is Artiva Biotherapeutics in?

Artiva Biotherapeutics is in the Healthcare sector

What industry is Artiva Biotherapeutics in?

Artiva Biotherapeutics is in the Biotechnology industry

What country is Artiva Biotherapeutics based in?

Artiva Biotherapeutics is headquartered in United States

Is Artiva Biotherapeutics in the S&P 500?

No, Artiva Biotherapeutics is not included in the S&P 500 index

Is Artiva Biotherapeutics in the NASDAQ 100?

No, Artiva Biotherapeutics is not included in the NASDAQ 100 index

Is Artiva Biotherapeutics in the Dow Jones?

No, Artiva Biotherapeutics is not included in the Dow Jones index

When was Artiva Biotherapeutics's last earnings report?

Artiva Biotherapeutics's most recent earnings report was on Nov 12, 2024

When does Artiva Biotherapeutics report earnings?

The next expected earnings date for Artiva Biotherapeutics is Feb 28, 2025

Should I buy Artiva Biotherapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions